We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Vitreous and Aqueous Penetration of Orally Administered Gatifloxacinin Humans—Reply

Seenu M. Hariprasad, MD; William F. Mieler, MD; Eric R. Holz, MD
Arch Ophthalmol. 2004;122(9):1409. doi:10.1001/archopht.122.9.1409.
Text Size: A A A
Published online


In reply

We are pleased to note Drs Fuller and Marcus' interest in our recentarticle.1 We agree with them that the fourth-generationfluoroquinolones, such as gatifloxacin and moxifloxacin, are poised to havean important role in the treatment and prophylaxis of endophthalmitis andother ophthalmic infections. We respectfully take issue, however, with thesuggestion that the intent of this investigation was to demonstrate the superiorityof gatifloxacin over moxifloxacin. In fact, studies are underway at our institutionthat investigate the intraocular penetration of moxifloxacin through variousroutes, including topical drops as well as a collagen shield delivery device.The point made in our article was that oral gatifloxacin is the first fourth-generation fluoroquinolone reported to achieve therapeuticlevels in the human vitreous—not that it was the best fourth-generation fluoroquinolone available. Although human dataare not currently available, future studies may in fact demonstrate that moxifloxacinachieves higher intravitreal concentration compared with gatifloxacin afteroral administration.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference